Charles River Laboratories International, Inc. (CRL)

Over the past six months, Charles River Laboratories' stock price has experienced a decline. Key events impacting the stock include Q2 CY2025 earnings, analyst rating changes, CFO transition, insider activity, and strategic collaborations. On August 6, 2025, CRL reported Q2 CY2025 results, beating Wall Street's revenue expectations. Several firms have updated their ratings and price targets. In September 2025, Charles River announced that CFO Flavia Pease would step down, with Michael Knell appointed as interim CFO. In August 2025, EVP Joseph W. Laplume sold 800 shares of the company's stock. In September 2025, CRL stock rose following new strategic oncology collaborations.

The provided search results do not explicitly detail the demand seasonality for Charles River Laboratories' products and services. However, the company's business is tied to the drug discovery and development lifecycle, which can be influenced by factors such as pharmaceutical R&D spending and biotech funding trends. The overall demand for its services can be impacted by broader trends in the biopharmaceutical industry.

Charles River Laboratories International, Inc. (CRL) is a global contract research organization (CRO) providing products and services to pharmaceutical, biotechnology, medical device, agricultural, and industrial chemical companies, as well as government agencies and academic institutions, to accelerate research and drug development. The company operates in the Healthcare sector, specifically in the Biotechnology: Commercial Physical & Biological Research industry, and also has a presence in Pharmaceuticals, Biotechnology, Gene therapy, Cell therapy, and Medical devices. CRL's core business is structured around three primary segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions.

Charles River Laboratories has a significant global presence, operating in over 20 countries with more than 150 facilities and approximately 20,000 to 21,000 employees worldwide. The company's headquarters are located in Wilmington, Massachusetts, USA. Its operations span North America, Europe, and Asia, with specific locations in countries such as Australia, Belgium, Brazil, Canada, China, Finland, France, Germany, Hungary, India, Ireland, Italy, Netherlands, Singapore, South Korea, Spain, Switzerland, and the United Kingdom.

In the past year, Charles River Laboratories has faced criticism from animal rights activists regarding its use of animals for pharmaceutical research. The Born Free USA animal welfare organization protested against CRL's plan to export endangered juvenile long-tail macaques to Cambodia for testing. The FDA's move to phase out animal testing requirements has been highlighted as a significant negative impact on CRL's core business.

Charles River Laboratories' ownership structure is primarily institutional, with institutional investors holding a significant majority of shares, around 90% to 98.91%. Major institutional owners include Vanguard Group Inc., Wellington Management Group Llp, and BlackRock, Inc. Individual insiders, including executive officers and board members, also own a portion of the company's shares.